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ORIGINAL ARTICLEDuodenal ulcer promoting gene 1 (dupA1) is associated with A2147G
clarithromycin-resistance mutation but not interleukin-8 secretion from
gastric mucosa in Iraqi patientsN. R. Hussein1, I. Tunjel2, H. S. Majed3, S. T. Yousif1, S. I. Aswad1 and M. S. Assaﬁ4
1) Department of Internal Medicine, The School of Medical Sciences, Faculty of Medicine, University of Duhok, Kurdistan Region, Iraq, 2) Department of Biology,
Faculty of Science, Fatih University, Istanbul, Turkey, 3) Nutrition Unit, Duhok Diabetes Centre, Duhok and 4) Department of Biology, Faculty of Sciences, University
of Zakho, Kurdistan Region, IraqAbstractHelicobacter pylori causes peptic ulceration and gastric adenocarcinoma. The aims were to study the inﬂuence of dupA1 positivity upon
interleukin-8 (IL-8) secretion from gastric mucosa and determine the prevalence of mutations responsible for clarithromycin and
ﬂuoroquinolone resistance. DNA was extracted from 74 biopsies and the virulence factors were studied. Levels of IL-8 in gastric mucosa
were measured using ELISA and the mutations responsible for clarithromycin and ﬂuoroquinolone resistance were determined using a
GenoType-HelicoDR assay. The prevalence of cagA in strains isolated from gastric ulcer (GU) and duodenal ulcer (DU) was signiﬁcantly
higher than those isolated from non-ulcer disease (NUD) (90% and 57.9% versus 33.3%; p 0.01). The vacA s1m1 genotype was more
prevalent in patients with DU (73.7%) and GU (70%) than in those with NUD (13.3%) (p 0.01). The prevalence of dupA1 was higher in
DU patients (36.8%) than those with GU (10%) and NUD (8.9%) (p 0.01). Multivariate analysis showed that a cagA+/vacA s1i1m2
virulence gene combination was independently associated with the developing peptic ulcer disease (PUD) with increased odds of
developing PUD (p 0.03; OR = 2.1). We found no signiﬁcant difference in the levels of IL-8 secretion in gastric mucosa infected with
H. pylori dupA-negative and H. pylori dupA1-positive strains (dupA-negative: mean ± median: 28 ± 26 versus 30 ± 27.1 for dupA1; p 0.6).
While 12 strains were clarithromycin resistant, only three isolates were levoﬂoxacin resistant. A signiﬁcant association was found
between dupA1 genotype and A2147G clarithromycin resistance mutation (p <0.01). Further study is needed to explore the relationship
between virulence factors and disease process and treatment failure.
© 2015 New Microbes and New Infections published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
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E-mail: doctornrs@yahoo.comIntroductionHelicobacter pylori infection is associated with peptic ulcer dis-
ease (PUD) and gastric cancer. Virulence factors such as cagA,
vacA and dupA play an important role in the pathogenesis of© 2015 New Microbes and New Infections published by El
This is an open access artiH. pylori-related diseases. Strains of H. pylori possessing cagA
have been shown to associate with a signiﬁcantly increased risk
for the development of atrophic gastritis, peptic ulcer disease
and gastric cancer [1]. The vacA and its polymorphism
contribute signiﬁcantly to the disease development process.
According to the segment region (s) and middle region (m) the
status of vacA can be classiﬁed into four subtypes: s1m1, s1m2,
s2m1 and s2m2. In vitro experiments showed that s1m1 strains
are the most cytotoxic, followed by s1m2 strains, whereas
s2m2 strains have no cytotoxic activity, and s2m1 strains are
rare [1]. Research showed that subjects infected with vacA s1
or m1 isolates have an increased risk of peptic ulcer and/orNew Microbe and New Infect 2015; 6: 5–10
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[1–3]. Rhead et al. have recently described a novel determinant
of VacA toxicity, the intermediate (i) region [4]. The duodenal
ulcer promoting gene A (dupA) is another virulence determi-
nant that has been shown to associate with duodenal ulcer
(DU) in some countries. Also, the presence of dupA was found
to be related to neutrophil inﬁltration and a high level of
interleukin-8 (IL-8) production by epithelial cells [5,6].
Furthermore, dupA was previously classiﬁed into two main
subtypes: the functional dupA with an extended open reading
frame (ORF) within jhp0917-19 (dupA1), and non-functional
dupA with an early stop codon to truncate the ORF (dupA2) [5].
Since the discovery of H. pylori, the mainstream treatment of
PUD has changed signiﬁcantly [7]. The use of antibiotics to
eradicate H. pylori infection is usually not chosen on the basis of
routine susceptibility testing because of the difﬁculty of growing
H. pylori. The eradication regimen should include a proton
pump inhibitor and more than one antibiotic [7]. Historically,
clarithromycin has been used as a ﬁrst-line treatment for
H. pylori. The eradication rate drops from 88% in the case of a
clarithromycin-susceptible strain to <20% in the case of clari-
thromycin resistance [7]. With ﬂuoroquinolones, which can be
used as a second line of treatment, resistance was also shown
to be correlated with treatment failure [8,9]. Because resis-
tance rates vary according to the country and patient charac-
teristics, the choice of antibiotics on the basis of susceptibility
pattern in the region might be an effective strategy to improve
H. pylori eradication [7]. Resistance to clarithromycin and ﬂu-
oroquinolone is the result of mutations and these mutations are
now well known [9–12]. Clarithromycin resistance is the result
of point mutations in the rrl gene encoding the 23S rRNA.
Three major mutations have been described: A2146C, A2146G
and A2147G [10]. The resistance of H. pylori to quinolones
results from point mutations in the gyrA gene encoding the A
subunit of the DNA gyrase, mainly at codons 87 and 91 [9,11].
Helicobacter pylori virulence factors and their relationship
with disease outcomes in Iraq were studied in this paper. In
addition, the association of dupA polymorphisms with IL-8
secretion from gastric mucosa was studied. Also, molecular
techniques were used to study the sensitivity pattern of H. pylori
to clarithromycin and ﬂuoroquinolone.Materials and methodsGastric biopsies
Gastric biopsies were obtained from 74 H. pylori+ patients from
Iraq undergoing routine upper gastrointestinal endoscopy to
investigate dyspepsia. Mean age ± standard deviation was
37 ± 13 years. Endoscopic diagnoses were: DU 19, gastric ulcer© 2015 New Microbes and New Infections published by Elsevier Ltd on behalf of European Soc
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice(GU) 10 and non-ulcer disease (NUD) 45. During gastroscopy,
biopsy samples were taken and placed in 1 mL of isosensitest
broth (Oxoid, Basingstoke, UK) containing 15% (volume/vol-
ume) glycerol and stored in liquid nitrogen. DNA was extracted
directly from the biopsy specimens and used for PCR-based
H. pylori typing.
The study protocol was approved by the Ethics and Research
Committees of the individual hospitals and all patients gave
informed consent to the study.
Antibiotic susceptibility
Helicobacter pylori antimicrobial susceptibility was investigated
using mutational analysis to clarithromycin and ﬂuoroquinolone
using the GenoType HelicoDR kit (Hain Lifescience, Nehren,
Germany) according to the manufacturer’s instructions. To
detect ﬂuoroquinolone resistance, four gyr87 wild-type probes
(gyr87WT1–gyr87WT4) and one mutant probe (gyr87MUT),
and one gyr91 wild-type probe (gyr91WT1) and three mutant
probes (gyr91MUT1–gyr91MUT3) were used to detect ﬂuo-
roquinolone resistance at positions 87 and 91, respectively. To
detect clarithromycin resistance, one wild-type probe (23SWT)
and three mutant probes (23SMUT1–23SMUT3) were used
with the presence of three controls: conjugate control (CC),
ampliﬁcation control (AC) and H. pylori (HP). When one of the
wild-type probes stained positive together with the gyr91WT
as well as 23SWT and no mutation band formed, the results
were interpreted as susceptible to the respective antibiotic.
The presence of a band at CC and AC meant that the CC and
AC were in the right frame whereas a band at HP implied the
presence of H. pylori according to the manufacturer’s
instruction.
Virulence factors genotyping
Thermal cycling for amplifying cagA was 95°C for 30 s, 50°C for
1 min, and 72°C for 2 min, for a total of 35 cycles. PCR
ampliﬁcation of cagA used previously described primers cag2
(50-GGAACCCTAGTCGGTAATG-30) and cag4 (50-
ATCTTTGAGCTTGTCTATCG-30) to amplify about 500-bp
product from the middle of cagA (PAI) [13]. For vacA signal and
middle region, thermal cycle conditions were 30 s at 95°C, 60 s
at 56°C and 90 s at 72°C, performed for 35 cycles. Primers
used for the middle region were vag-F (50-CAATCTGTC-
CAATCAAGCGAG-30), and vag-R (50-GCGTCTAAA-
TAATTCCAAGG-30). For the signal region, A3436 (50-
ATGGAAATACAACAAACACAC-30) and C1226 (50-
CTGCTTGAATGCGCCAAAC-30) primers were used [14].
The PCR conditions for vacA i region were as follows: the
template mixtures were ampliﬁed 35 cycles with primers VacF1
(50-GTTGGGATTGGGGGAATGCCG-30) and C1R (50-
TTAATTTAACGCTGTTTGAAG-30) for i1 region and VacF1iety of Clinical Microbiology and Infectious Diseases, NMNI, 6, 5–10
nses/by-nc-nd/4.0/)
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at 95°C for 30 s, 53°C for 1 min, and 72°C for 30 s [4]. The
dupA was ampliﬁed using three sets of primers: DupA-WXF (50-
GATATACCATGGATGAGTTCYRTAYTAACAGAC) and
DAR1 (50-TTAAATACTCTTCCTTATAAGTTTCTTGG);
JHP0919R2 (50-GCCCACCAGTTGCAAAAACAAATGAAC)
and DupA918F (50-CCTATATCGCTAACGCGCTC); and
dupA-F0 (50-TGG CGT GTG GCA GTC TAA TGC) and
dupA-R1 (50-GCT CAA CAA AAT GCC CAC CAG TCG C)
then, the ampliﬁed genes were sequenced on both strands using
different primers (Table 1).
Mucosal IL-8 level
ELISA was used to measure the IL-8 levels in the antral biopsy
specimens (R&D Systems, Minneapolis, MN) according to the
manufacturer’s instructions. Brieﬂy, samples were homoge-
nized ﬁrst and then aliquots of supernatant tissues were ob-
tained by centrifugation. The total protein in the supernatants
was measured by using the Bradford assay (Bio-Rad, Rich-
mond, CA). ELISA sensitivities were approximately 5 pg/mL
for IL-8.
Data analysis
Statistical analysis of data was performed by using stepwise
logistic regression and the chi-squared test with signiﬁcance set
at a p < 0.05 using MINITAB 15 software (Minitab Ltd., Coventry,
UK).ResultsAssociation between virulence factors and clinical
outcomes cagA, vacA, vacAs, m, combinations and dupA
status
The prevalence of cagA+ strains in the study was 47.3% (35/74).
Regarding the vacA genotypes, 70/74 (94.6%) of the studiedTABLE 1. Oligonucleotide primers used for DNA sequencing
of Helicobacter pylori dupA
Primers Sequences
DupA918F CCTATATCGCTAACGCGCTC(9)
JHP0919R2 GCCCACCAGTTGCAAAAACAAATGAAC(9)
DAR1 TTAAATACTCTTCCTTATAAGTTTCTTGG(9)
DupA-WXF GATATACCATGGATGAGTTCYRTAYTAACAGAC(9)
dupA-F0 TGG CGT GTG GCA GTC TAA TGC(26)
dupA-F1 GCA AAC GCT CAA ACT ATT GCC(26)
dupA-F2 ATG TTT CTT GGT TTA GAG GG(26)
dupA-F3 CAG AAC ACA AGC TTT AAA TGA ATT G(26)
dupA-F4 ATG AGT TCT ATA CTA ACA GAC TTTGAG CC(26)
dupA-F5 GGT TTC TAC TGA CAG AGC AC(26)
dupA-F6 GAT AAT TGG TAG CAC AGG AAG CGG(26)
dupA-F7 GGC TCT AGC GAA CAA GAT TTT AAT GAG(26)
dupA-R1 GCT CAA CAA AAT GCC CAC CAG TCG C(26)
© 2015 New Microbes and New Infections published by Elsevier Ltd on beh
This is an open access artistrains typed as vacAs1. The vacAm2 was found in 47 (63.51%)
of our 74 samples. In addition, the vacA i1 genotype was found
in 42 of the 74 (56.76%). Regarding the combination of the s
region, i region and m region of vacA, the prevalence of the
genotype vacA s1i2m2 was highest (37.8%) (28/74), the prev-
alences of genotypes vacA s1i1m1 and s1i2m1 were 36.49%
(27/74) and 20% (15/74), respectively. The genotype vacA
s212m2 was found in only four patients, all of them with NUD
(Table 2).
dupA was previously classiﬁed into two main groups: the
common extended ORF within jhp0917-19 (dupA1), and dupA
with an early stop codon to truncate the ORF (dupA2) [15]. In
our study the dupA1 genotype was found in 12/74 (16.2%) and
only 5/74 (6.7%) patients had the dupA2 genotype.
The effect of the virulence factors on the disease
outcome
DNA was extracted from gastric mucosa of 74 H. pylori-positive
patients (19 DU, 10 GU and 45 NUD). The prevalence of cagA+
strains isolated from GU and DU patients was found to be
signiﬁcantly higher than those isolated from patients with NUD
(90% and 57.9% versus 33.3%; p 0.01 for both).
All H. pylori strains isolated from patients with DU and GU
had the vacAs1 genotype, whereas 94.6% of the strains isolated
from patients with NUD had the vacAs1 genotype (p >0.05).
The vacAm1 genotype was found to be more prevalent in
strains isolated from DU (73.7%) and GU (70%) than those
from NUD (14%) (p <0.01). The prevalences of vacAi1 strains
isolated from DU and GU were 89.47% and 90%, respectively,
and were signiﬁcantly higher than that found in NUD (33.3%) (p
0.01 for both). The vacA s1i1m1 genotype was more prevalent
in patients with DU (73.7%) and GU (70%) than those with
NUD (13.3%) (p 0.01). The vacA s2i2m2 genotype was only
found in patients with NUD (8.9%) (Table 2). Seventeen
(22.9%) of our 74 strains typed as dupA-positive, among which
12 strains typed as dupA1. The prevalence of dupA1 was higher
in DU (36.8%) than in GU (10%) and NUD (8.9%) (p 0.01).
Multivariate analysis showed that cagA+/ vacA s1i1m2 strains
were independently associated with the developing PUD with
increased odds of developing PUD (p 0.03; OR = 2.1).TABLE 2. Association of vacA polymorphisms with clinical
outcomes
Outcome (n)
s1i1m1,
n (%)
s1i2m1,
n (%)
s1i2m2,
n (%)
s2i2m2,
n (%)
DU (19) 14 (73.7)* 3 (15.8) 2 (10.5) 0 (0)
GU (10) 7 (70)* 3 (30) 0 (0) 0 (0)
NUD (45) 6 (13.3) 9 (20) 26 (57.8) 4 (8.9)
Total (74) 27 (36.4) 15 (20.2) 28 (37.8) 4 (5.34)
*Signiﬁcant association.
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FIG. 1. Interleukin-8 levels in gastric biopsies from cagA-negative Hel-
icobacter pylori-infected tissues, dupA1 H. pylori-infected tissues and
dupA2 H. pylori-infected tissues. No signiﬁcant differences were found; *
indicates outlier.
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resistance and its association with virulence factors
Two mutations were associated with clarithromycin resistance:
A2147G and A2146G. Levoﬂoxacin resistance is associated
with D91N mutation. The prevalence of these mutations was
studied. Overall in 74 patients, 12/72 (16.2%) strains were
clarithromycin resistant, of which ten carried the A2147G
mutation (Table 3). Only three patients were levoﬂoxacin
resistant. The A2147G mutation was found in 8.1% in patients
with NUD, 4.1% in patients with DU and 1.4% in patients with
GU. The other mutation, A2146G, was found in only 2.7% of
patients. 1.4% of patients with NUD and 1.4% of patients with
DU tested positive for the presence of this mutation. The
levoﬂoxacin-resistance mutation (D91N) was found in three of
the 74 patients (4.1%; one DU, one GU and one NUD).
A signiﬁcant association was found between dupA1 genotype
and A2147G clarithromycin resistance mutation (p <0.01)
(Table 3). No signiﬁcant association was found between
A2146G or D91N and virulence factors.
The association between IL-8 and dupA status
To compare the levels of gastric IL-8 secretions, we classiﬁed
our samples into three groups: dupA-negative, dupA1 and
dupA2. We found no signiﬁcant difference between the levels of
IL-8 secretion in gastric mucosa infected with H. pylori dupA-
negative mucosa and H. pylori dupA1-positive strains (dupA-
negative: mean ± median: 28 ± 26 versus 30 ± 27.1 for dupA1; p
0.6). Also, no signiﬁcant difference was found between H. pylori
dupA-negative mucosa and H. pylori dupA2-positive strains
(28 ± 26 versus 35 ± 26; p 0.7) (Fig. 1). Also, we classiﬁed our
samples into two groups: samples infected with cagA-positive
strains and those infected with cagA-negative strains. It was
found that the same levels of IL-8 were elicited in biopsies
infected with cagA-positive strains and cagA-negative strainsTABLE 3. The relation between antibiotic resistance and
virulence factors
Clarithromycin resistance Levoﬂuxacin resistance
A2147G A2146G D91N
cagA 27% 0% 6%
dupA1 50%* 0% 0%
dupA2 0% 0% 0%
vacA s1 13% 3% 4%
vacA s2 25% 0% 0%
vacA m1 15% 0% 7%
vacA m2 13% 4% 2%
vacA i1 15% 0% 5%
vacA i2 12% 6% 3%
vacA s1m1 15% 0% 8%
vacA s1m2 12% 5% 2%
vacA s2m2 25% 0% 0%
*Signiﬁcant association.
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(Fig. 2).DiscussionHelicobacter pylori infection is associated with peptic ulceration
and gastric adenocarcinoma, the second highest cause of cancer
deaths worldwide [7]. Clarithromycin and ﬂuoroquinolone are
two drugs used widely in the eradication of H. pylori. Resistance
to these drugs is emerging and presents a challenge. Studies all
over the world have reported resistance to clarithromycin and
ﬂuoroquinolone [16–18]. Proton pump inhibitor–
clarithromycin-containing triple therapy without previous sus-
ceptibility testing should be abandoned when the
clarithromycin-resistance rate in the region is between 15 andFIG. 2. Interleukin-8 levels in gastric biopsies from cagA-negative Hel-
icobacter pylori-infected tissues and cagA-positive H. pylori-infected tis-
sues. No signiﬁcant differences were found; * indicates outlier.
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resistance rate to these medications. It was found that 16.2% of
the strains used in this study were clarithromycin resistant.
These results need to be conﬁrmed by culture and sensitivity
and if true, then clarithromycin-containing triple therapy should
not be considered for the eradication of H. pylori because of the
high failure rate. In addition, only three (4%) patients were
levoﬂoxacin resistant. This is a low resistance rate in compar-
ison to isolates from Belgium, France, Italy and Germany where
higher resistance rates to ciproﬂoxacin or levoﬂoxacin ranging
between 16.8% and 23% [16,17] were found. Also, higher
resistance rates (ciproﬂoxacin 33.8%; levoﬂoxacin 21.5%) have
been observed in Japan [18]. These differences in resistance
rate could be attributed to geographical region and drug usage
differences.
The study of H. pylori virulence factors in populations is
important because they contribute to disease risk. For example,
in Iran, where gastric cancer is common, more than 75% of
H. pylori strains are cagA positive [2]. We looked within our
populations for the associations between virulence factors and
PUD. In agreement with previous reports from Iraq [19–21], a
signiﬁcant association between cagA status and PUD was
observed. Also, research from a neighbouring country, Turkey,
has shown results similar to those from Iraq [3]. Next, we
examined the association between vacA polymorphisms and
clinical outcomes. The vacA s1, m1 and s1m1 genotypes were
signiﬁcantly associated with PUD. This is in agreement with
other reports from Iraq and other countries [2,22]. The vacA i
region polymorphisms are a relatively a new virulence deter-
minant and have not been examined thoroughly. It was previ-
ously shown that the vacA i1 genotype is associated with gastric
cancer in Iran [4]. We studied the association between vacA i
region polymorphisms and clinical outcomes. It was found that
vacA i1 is signiﬁcantly associated with GU and DU. A previous
report from Iraq showed a signiﬁcant relationship between vacA
i1 and GU but not DU [2]. However, the sample size used in
the previous study was small and more study was suggested to
investigate such a relationship.
Multivariate analysis showed that cagA+/ vacA s1i1m2 strains
were independently associated with the developing PUD.
Other virulence factors, solely or in combination, could not
show any independent association with clinical outcome.
Therefore we suggest that single bacterial factors could not
solely explain the outcomes of gastroduodenal diseases.
The dupA is a virulence factor that comprises both jhp0917
and jhp0918. Lu et al. found a signiﬁcant relationship between
dupA and DU, and the presence of dupA was related to
neutrophil inﬁltration and a high level of IL-8 production by
epithelial cells [6]. Since then, contradicting results reported
about the relationships of dupA and clinical outcomes [5]. Then,© 2015 New Microbes and New Infections published by Elsevier Ltd on beh
This is an open access artidupA was classiﬁed into dupA1 (functional) and dupA2 (non-
functional, including the originally described form, in which the
the ORF was broken by a stop codon) [5]. Such a classiﬁcation
helped the explanation of contradicting results. In agreement
with a previous report from Iraq, we found a signiﬁcant rela-
tionship between dupA1 and DU [15]. In addition, a previous
report showed an association between dupA status and failure
of H. pylori eradication [23]. No explanation was given in that
report about how dupA could prevent the eradication of this
bacteria. We found a novel association between dupA1 and
A2147G, a mutation responsible for clarithromycin resistance.
Such an association is difﬁcult to explain and warrants further
study. However, this relationship might be because dupA1 may
increase the pro-inﬂammatory factors including reactive oxy-
gen species and these factors may help to induce mutations in
the bacteria. Further study is needed to conﬁrm such a result
and explore how these genotypes may have become
associated.
Lu et al. found that the presence of dupA was related to
neutrophil inﬁltration and a high level of IL-8 production [6].
We also previously reported that dupA1 correlates with clinical
outcome and gastric IL-8 levels in Iraqi H. pylori-infected sam-
ples [15]. However, such a relationship could not be obtained in
this report. This contradiction is difﬁcult to explain and war-
rants further studies.
To conclude, there is a high resistance rate to clarithromycin
in our region. Such results need to be conﬁrmed and, if true, it
should be discussed whether clarithromycin should be dropped
from the ﬁrst-line eradication regimen. Univariate analysis
showed that cagA, vacA s1, m1, and s1m1 genotypes were
signiﬁcantly associated with PUD. However, multivariate study
showed that only cagA+/ vacA s1i1m2 combination is an inde-
pendent marker for disease outcome. dupA1 was shown to be
associated with DU and clarithromycin resistance but not IL-8
secretion. The association between dupA1 and clarithromycin
may help to explain the previous report of the association
between dupA and treatment failure. Further study is needed to
explore the relationship between dupA polymorphisms and
clinical outcomes and drug resistance.Conﬂict of interestThe authors declare that there are no conﬂicts of interest.References[1] Atherton JC. The pathogenesis of Helicobacter pylori induced gastro-
duodenal diseases. Annu Rev Pathol Mech Dis 2006;1(1):63–96.alf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 5–10
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
10 New Microbes and New Infections, Volume 6 Number C, July 2015 NMNI[2] Hussein NR, Mohammadi M, Talebkhan Y, Doraghi M, Letley DP,
Muhammad MK, et al. Differences in virulence markers between Hel-
icobacter pylori strains from Iraq and those from Iran: potential
importance of regional differences in H. pylori-associated disease. J Clin
Microbiol 2008;46(5):1774–9.
[3] Saribasak H, Salih BA, Yamaoka Y, Sander E. Analysis of Helicobacter
pylori genotypes and correlation with clinical outcome in Turkey. J Clin
Microbiol 2004;42:1648–51.
[4] Rhead JL, Letley DP, Mohammadi M, Hussein N, Mohagheghi MA,
Eshagh Hosseini M, et al. A new Helicobacter pylori vacuolating cyto-
toxin determinant, the intermediate region, is associated with gastric
cancer. Gastroenterology 2007;133(3):926–36.
[5] Hussein NR, Argent RH, Marx CK, Patel SR, Robinson K, Atherton JC.
Helicobacter pylori dupA is polymorphic, and its active form induces
proinﬂammatory cytokine secretion by mononuclear cells. J Infect Dis
2010;202(2):261–9.
[6] Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting
gene of Helicobacter pylori. Gastroenterology 2005;128(4):833–48.
[7] Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon TR,
Bazzoli F, et al. Management of Helicobacter pylori infection the Maas-
tricht IV/Florence Consensus report. Gut 2012;61(5):646–64.
[8] Nishizawa T, Suzuki H, Kurabayashi K, Masaoka T, Muraoka H, Mori M,
et al. Gatiﬂoxacin resistance and mutations in gyrA after unsuccessful
Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother
2006;50(4):1538–40.
[9] Nishizawa T, Suzuki H, Umezawa A, Muraoka H, Iwasaki E, Masaoka T,
et al. Rapid detection of point mutations conferring resistance to ﬂu-
oroquinolone in gyrA of Helicobacter pylori by allele-speciﬁc PCR. J Clin
Microbiol 2007;45(2):303–5.
[10] Oleastro M, Ménard A, Santos A, Lamouliatte H, Monteiro L,
Barthélémy P, et al. Real-time PCR assay for rapid and accurate
detection of point mutations conferring resistance to clarithromycin in
Helicobacter pylori. J Clin Microbiol 2003;41(1):397–402.
[11] van Doorn LJ, Glupczynski Y, Kusters JG, Mégraud F, Midolo P, Maggi-
Solcà N, et al. Accurate prediction of macrolide resistance in Heli-
cobacter pylori by a PCR Line Probe Assay for detection of mutations in
the 23S rRNA gene: multicenter validation study. Antimicrob Agents
Chemother 2001;45(5):1500–4.
[12] Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L,
et al. Evaluation of a New Test, GenoType HelicoDR, for molecular© 2015 New Microbes and New Infections published by Elsevier Ltd on behalf of European Soc
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licedetection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol
2009;47(11):3600–7.
[13] Rudi J, Kolb C, Maiwald M, Kuck D, Sieg A, Galle PR, et al. Diversity of
Helicobacter pylori vacA and cagA genes and relationship to VacA and
CagA protein expression, cytotoxin production, and associated dis-
eases. J Clin Microbiol 1998;36(4):944–8.
[14] Atherton JC, Cao P, Peek Jr RM, Tummuru MK, Blaser MJ, Cover TL.
Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Asso-
ciation of speciﬁc vacA types with cytotoxin production and peptic
ulceration. J Biol Chem 1995;270(30):17771–7.
[15] Hussein NR, Abdullah SM, Salih AM, Assaﬁ MA. dupA1 Is associated
with duodenal ulcer and high interleukin-8 secretion from the gastric
mucosa. Infect Immun 2012;80(8):2971–2.
[16] Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of
primary ﬂuoroquinolone resistance among clinical isolates of Heli-
cobacter pylori at a University Hospital in Southern Taiwan. Heli-
cobacter 2009;14(1):61–5.
[17] Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M,
Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe
and its relationship to antibiotic consumption. Gut 2013;62(1):34–42.
[18] Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M,
et al. Primary levoﬂoxacin resistance and gyrA/B mutations among
Helicobacter pylori in Japan. Helicobacter 2006;11(4):243–9.
[19] Abdullah SM, Hussein NR, Salih AM, Merza MA, Goreal AA,
Odeesh OY, et al. Infection with Helicobacter pylori strains carrying
babA2 and cagA is associated with an increased risk of peptic ulcer
disease development in Iraq. Arab J Gastroenterol 2012;13(4):166–9.
[20] Hussein NR, Napaki SM, Atherton JC. A study of Helicobacter pylori-
associated gastritis patterns in Iraq and their association with strain
virulence. Saudi J Gastroenterol 2009;15(2):125.
[21] Salih AM, Goreal A, Hussein NR, Abdullah SM, Hawrami K, Assaﬁ M.
The distribution of cagA and dupA genes in Helicobacter pylori strains in
Kurdistan region, northern Iraq. Ann Saudi Med 2012;33(3):290–3.
[22] Matsunari O, Shiota S, Suzuki R, Watada M, Kinjo N, Murakami K, et al.
Association between Helicobacter pylori virulence factors and gastro-
duodenal diseases in Okinawa, Japan. J Clin Microbiol 2012;50(3):
876–83.
[23] Shiota S, Nguyen LT, Murakami K, Kuroda A, Mizukami K, Okimoto T,
et al. Association of Helicobacter pylori dupA with the failure of primary
eradication. J Clin Gastroenterol 2012;46(4):297–301.iety of Clinical Microbiology and Infectious Diseases, NMNI, 6, 5–10
nses/by-nc-nd/4.0/)
